Publications by authors named "J Arita"
Aim: Constitutional indocyanine green (ICG) excretory defects must be distinguished when assessing liver function. The absence of OATP1B3 expression due to homogenous alterations in the SLCO1B3 gene has been recently reported to induce ICG excretory defects; however, its association with the clinical examinations and the clinical implications of heterogeneous SLCO1B3 gene alteration remain unclear.
Methods: OATP1B3 expression was evaluated in 49 patients who underwent hepatectomy after evaluation of the ICG retention rate at 15 min (ICGR15) and technetium-99 m-galactosyl serum albumin (99mTc-GSA) hepatic scintigraphy.
A 59-year-old woman was diagnosed with a pancreatic neuroendocrine tumor (P-NET; Grade 3, Ki67: 25%) with multiple liver and lymph node metastases and started chemotherapy with streptozosin (500 mg/m/day) in combination with lanreotide acetate (120 mg). After six courses of (daily) streptozosin, the patient had progressive disease, as assessed by computed tomography (CT), and peptide receptor radionuclide therapy (PRRT) was started as second-line treatment. As PRRT was remarkably successful and the tumor shrank, surgery was performed to resect the primary pancreatic tumor, liver metastases, and lymph node metastases.
View Article and Find Full Text PDFArticle Synopsis
- This study on pancreatic neuroendocrine tumors (PanNETs) explores the use of biomarkers like DAXX/ATRX and H3K36me3 alongside traditional factors like WHO grade and tumor size to predict recurrence risk after surgery.
- Researchers found that 16.2% of primary PanNETs had losses of DAXX or ATRX, indicating a higher risk of recurrence and correlating better with postoperative outcomes than WHO grade.
- A new risk stratification algorithm was proposed, categorizing patients into very low-risk, low-risk, and high-risk groups based on DAXX/ATRX status and tumor characteristics, while also addressing the variability of expression patterns in different tumors.
Background: The optima preoperative biliary drainage before pancreaticoduodenectomy in patients with biliary tract and pancreatic cancer remains controversial.
Methods: A total of 898 patients who underwent preoperative biliary drainage via endoscopic retrograde biliary drainage, endoscopic transnasal biliary drainage, or percutaneous transhepatic biliary drainage before pancreaticoduodenectomy for biliary tract and pancreatic cancer were included. Perioperative and long-term outcomes were analyzed.